Medy-Tox Inc Cash Flow Conversion Efficiency
Medy-Tox Inc cash flow conversion efficiency. Based on the latest financial reports, Medy-Tox Inc (086900) has a cash flow conversion efficiency ratio of 0.041x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩19.03 Billion ≈ $12.90 Million USD) by net assets (₩467.65 Billion ≈ $316.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Medy-Tox Inc (2013–2024)
Cash flow conversion efficiency of Medy-Tox Inc from 2013 to 2024. This chart illustrates how Medy-Tox Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 086900 stock price and chart for real-time trading data and today's change.
Medy-Tox Inc Cash Flow Conversion Ratio Explained
Medy-Tox Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Medy-Tox Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medy-Tox Inc ranked by their cash flow conversion efficiency. Also see market cap of Medy-Tox Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SRINANAPORN MARKETING
BK:SNNP-R
|
N/A |
|
Qibu Co Ltd
SHG:603557
|
-0.263x |
|
JW Pharmaceutical Corp
KO:001065
|
0.104x |
|
Corby Spirit and Wine Limited
TO:CSW-A
|
-0.088x |
|
Firm Capital Mortgage Invest Corp
TO:FC
|
0.023x |
|
SilverBox Corp V
NYSE:SBXE
|
-0.001x |
|
Compagnie d Entreprises CFE SA
BR:CFEB
|
0.362x |
|
Bali Towerindo Sentra Tbk
JK:BALI
|
0.048x |
Annual Cash Flow Conversion Efficiency for Medy-Tox Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Medy-Tox Inc from 2013 to 2024. Review 086900 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩470.78 Billion ≈ $319.04 Million |
₩36.89 Billion ≈ $25.00 Million |
0.078x | +174.98% |
| 2023-12-31 | ₩474.48 Billion ≈ $321.55 Million |
₩13.52 Billion ≈ $9.16 Million |
0.028x | -53.44% |
| 2022-12-31 | ₩428.04 Billion ≈ $290.08 Million |
₩26.20 Billion ≈ $17.75 Million |
0.061x | +22.47% |
| 2021-12-31 | ₩399.48 Billion ≈ $270.72 Million |
₩19.97 Billion ≈ $13.53 Million |
0.050x | -56.80% |
| 2020-12-31 | ₩241.40 Billion ≈ $163.59 Million |
₩27.93 Billion ≈ $18.93 Million |
0.116x | -11.05% |
| 2019-12-31 | ₩259.15 Billion ≈ $175.62 Million |
₩33.70 Billion ≈ $22.84 Million |
0.130x | -40.35% |
| 2018-12-31 | ₩252.59 Billion ≈ $171.17 Million |
₩55.07 Billion ≈ $37.32 Million |
0.218x | -26.10% |
| 2017-12-31 | ₩191.65 Billion ≈ $129.88 Million |
₩56.55 Billion ≈ $38.32 Million |
0.295x | -19.46% |
| 2016-12-31 | ₩147.68 Billion ≈ $100.08 Million |
₩54.10 Billion ≈ $36.66 Million |
0.366x | +85.86% |
| 2015-12-31 | ₩113.48 Billion ≈ $76.91 Million |
₩22.37 Billion ≈ $15.16 Million |
0.197x | -84.74% |
| 2014-12-31 | ₩81.59 Billion ≈ $55.29 Million |
₩105.38 Billion ≈ $71.41 Million |
1.292x | +372.27% |
| 2013-12-31 | ₩60.68 Billion ≈ $41.13 Million |
₩16.60 Billion ≈ $11.25 Million |
0.273x | -- |
About Medy-Tox Inc
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and … Read more